C4 Therapeutics (CCCC) Research & Development (2019 - 2026)

C4 Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $24.6 million for Q1 2026.

• On a quarterly basis, Research & Development fell 9.11% year-over-year to $24.6 million in Q1 2026; TTM through Mar 2026 was $101.8 million, a 11.64% decrease from a year earlier, with the FY2025 full-year figure at $104.2 million, down 5.78% from the prior year.
• Research & Development declined to $24.6 million in Q1 2026 per CCCC's latest filing, from $25.0 million in the prior quarter.
• Across five years, Research & Development topped out at $32.5 million in Q4 2024 and bottomed at $22.5 million in Q1 2024.
• The 5-year median for Research & Development is $28.3 million (2023), against an average of $27.9 million.
• Across the five-year window, Research & Development soared 34.51% in 2022 and slipped 23.16% in 2025, its largest moves.
• Year by year, Research & Development stood at $30.7 million in 2022, then fell by 0.85% to $30.4 million in 2023, then increased by 6.98% to $32.5 million in 2024, then declined by 23.16% to $25.0 million in 2025, then slipped by 1.51% to $24.6 million in 2026.
• Per Business Quant, the three latest CCCC Research & Development figures stand at $24.6 million (Q1 2026), $25.0 million (Q4 2025), and $26.0 million (Q3 2025).